The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Cancer Risk Associated with Use of Metformin and Sulfonylurea in Type 2 Diabetes: A Meta-Analysis
Open accessAbstract
Objective.: Oral antidiabetic drugs (including metformin and sulfonylurea) may play a role in the relationship between type 2 diabetes and cancer. To quantify the association between metformin and sulfonylurea and the risk of cancer, we performed a meta-analysis of available studies on the issue. Materials and Methods.: We performed a MEDLINE search for observational studies that investigated the risk of all cancers and specific cancer sites in relation to use of metformin and/or sulfonylurea among patients with type 2 diabetes mellitus. Fixed- and random-effect models were fitted to estimate the summary relative risk (RR). Between-study heterogeneity was tested using χ2 statistics and measured with the I2 statistic. Publication bias was evaluated using funnel plot and Egger's regression asymmetry test. Results.: Seventeen studies satisfying inclusion criteria and including 37,632 cancers were evaluated after reviewing 401 citations. Use of metformin was associated with significantly decreased RR of all cancers (summary RR 0.61, 95% confidence interval [CI] 0.54–0.70), colorectal cancer (0.64, 95% CI 0.54–0.76), and pancreatic cancer (0.38, 95% CI 0.14–0.91). With the exception of colorectal cancer, significant between-study heterogeneity was observed. Evidence of publication bias for metformin-cancer association was also observed. There was no evidence that metformin affects the risk of breast and prostate cancers, nor that sulfonylurea affects the risk of cancer at any site. Conclusions.: Metformin, but not sulfonylurea, appears to reduce subsequent cancer risk. This has relevant implications in light of the exploding global epidemic of diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections
King, H., Aubert, R. E., & Herman, W. H. (1998) · Diabetes Care · doi:10.2337/diacare.21.9.1414 · Cited by 6,311
The combination of estimates from different experiments
Cochran, W. G. (1954) · Biometrics · doi:10.2307/3001666 · Cited by 5,380
TSC2 Mediates Cellular Energy Response to Control Cell Growth and Survival
Inoki, K., Zhu, T., & Guan, K.-L. (2003) · Cell · doi:10.1016/s0092-8674(03)00929-2 · Cited by 3,914
AMP-Activated Protein Kinase in Metabolic Control and Insulin Signaling
Towler, M. C., & Hardie, D. G. (2007) · Circulation Research · doi:10.1161/01.res.0000256090.42690.05 · Cited by 1,253
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124
Oral Antidiabetic Agents: Current Role in Type 2 Diabetes Mellitus
Krentz, A. J., & Bailey, C. J. (2005) · Drugs · doi:10.2165/00003495-200565030-00005 · Cited by 1,108
Glycemic index, glycemic load, and chronic disease risk—a meta-analysis of observational studies
Barclay, A. W., Petocz, P., McMillan-Price, J., Flood, V. M., Prvan, T., Mitchell, P., & Brand-Miller, J. C. (2008) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/87.3.627 · Cited by 1,061 · cited 1×
“The mechanisms are yet to be investigated, but insulin resistance with secondary hyperinsulinemia is the most frequently proposed hypothesis [3–5], although hyperglycemia itself seems to promote carcinogenesis [6].”
BackgroundMetformin is an AMP kinase-dependent growth inhibitor for breast cancer cells
Zakikhani, M., Dowling, R., Fantus, I. G., Sonenberg, N., & Pollak, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1500 · Cited by 1,048
New Users of Metformin Are at Low Risk of Incident Cancer
Libby, G., Donnelly, L. A., Donnan, P. T., Alessi, D. R., Morris, A. D., & Evans, J. M. M. (2009) · Diabetes Care · doi:10.2337/dc08-2175 · Cited by 996
Thomas, N., K, S., & Kapoor, N. (2016) · A Practical Guide to Diabetes Mellitus · doi:10.5005/jp/books/12651_7 · Cited by 943
Bowker, S. L., Majumdar, S. R., Veugelers, P., & Johnson, J. A. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1558 · Cited by 933
Buzzai, M., Jones, R. G., Amaravadi, R. K., Lum, J. J., DeBerardinis, R. J., Zhao, F., Viollet, B., & Thompson, C. B. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4447 · Cited by 923
Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis
DeCensi, A., Puntoni, M., Goodwin, P., Cazzaniga, M., Gennari, A., Bonanni, B., & Gandini, S. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0157 · Cited by 918
LKB1-Dependent Signaling Pathways
Alessi, D. R., Sakamoto, K., & Bayascas, J. R. (2006) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.75.103004.142702 · Cited by 788
Antidiabetic Therapies Affect Risk of Pancreatic Cancer
Li, D., Yeung, S. J., Hassan, M. M., Konopleva, M., & Abbruzzese, J. L. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.04.013 · Cited by 584
Giovannucci, E., & Michaud, D. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.050 · Cited by 543
Metabolic syndrome, hyperinsulinemia, and colon cancer: a review
Giovannucci, E. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.3.836s · Cited by 531
Metformin Associated With Lower Cancer Mortality in Type 2 Diabetes
Landman, G. W. D., Kleefstra, N., van Hateren, K. J. J., Groenier, K. H., Gans, R. O. B., & Bilo, H. J. G. (2010) · Diabetes Care · doi:10.2337/dc09-1380 · Cited by 502
Diet and exercise signals regulate SIRT3 and activate AMPK and PGC-1α in skeletal muscle
Palacios, O. M., Carmona, J. J., Michan, S., Chen, K. Y., Manabe, Y., III, J. L. W., Goodyear, L. J., & Tong, Q. (2009) · Aging · doi:10.18632/aging.100075 · Cited by 487
Long-Term Metformin Use Is Associated With Decreased Risk of Breast Cancer
Bodmer, M., Meier, C., Krähenbühl, S., Jick, S. S., & Meier, C. R. (2010) · Diabetes Care · doi:10.2337/dc09-1791 · Cited by 466
Understanding the benefit of metformin use in cancer treatment
Dowling, R. J., Goodwin, P. J., & Stambolic, V. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-33 · Cited by 409
Insulin, Glucose, Insulin Resistance, and Pancreatic Cancer in Male Smokers
Stolzenberg-Solomon, R. Z. (2005) · JAMA · doi:10.1001/jama.294.22.2872 · Cited by 400
Metformin: Taking away the candy for cancer?
Jalving, M., Gietema, J. A., Lefrandt, J. D., Jong, S. D., Reyners, A. K. L., Gans, R. O. B., & Vries, E. G. E. D. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.06.012 · Cited by 380
Lee, M.-S., Hsu, C.-C., Wahlqvist, M. L., Tsai, H.-N., Chang, Y.-H., & Huang, Y.-C. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-20 · Cited by 380
Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients
Yang, Y., Hennessy, S., & Lewis, J. D. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.07.011 · Cited by 350
Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies
Pisani, P. (2008) · Archives of Physiology and Biochemistry · doi:10.1080/13813450801954451 · Cited by 329
Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma
Hassan, M. M., Curley, S. A., Li, D., Kaseb, A., Davila, M., Abdalla, E. K., Javle, M., Moghazy, D. M., Lozano, R. D., Abbruzzese, J. L., et al. (2010) · Cancer · doi:10.1002/cncr.24982 · Cited by 309
Donadon, V., Balbi, M., Mas, M. D., Casarin, P., & Zanette, G. (2010) · Liver International · doi:10.1111/j.1478-3231.2010.02223.x · Cited by 292
Belfiore, A., & Malaguarnera, R. (2011) · Endocrine-Related Cancer · doi:10.1530/erc-11-0074 · Cited by 272
Metformin Use and Mortality in Ambulatory Patients With Diabetes and Heart Failure
Aguilar, D., Chan, W., Bozkurt, B., Ramasubbu, K., & Deswal, A. (2011) · Circulation: Heart Failure · doi:10.1161/circheartfailure.110.952556 · Cited by 203
Noto, H., Tsujimoto, T., Sasazuki, T., & Noda, M. (2011) · Endocrine Practice · doi:10.4158/ep10357.ra · Cited by 168
Bosco, J. L. F., Antonsen, S., Sørensen, H. T., Pedersen, L. H., & Lash, T. L. (2011) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0817 · Cited by 166
Bowker, S. L., Yasui, Y., Veugelers, P., & Johnson, J. A. (2010) · Diabetologia · doi:10.1007/s00125-010-1750-8 · Cited by 165
AMP-activated protein kinase pathway: a potential therapeutic target in cardiometabolic disease
Wong, A. K. F., Howie, J., Petrie, J. R., & Lang, C. C. (2009) · Clinical Science · doi:10.1042/cs20080066 · Cited by 165
Metabolic syndrome, hyperinsulinemia, and cancer
Hsu, I. R., Kim, S. P., Kabir, M., & Bergman, R. N. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.3.867s · Cited by 158
Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials
Johnson, J. A., & Bowker, S. L. (2010) · Diabetologia · doi:10.1007/s00125-010-1933-3 · Cited by 157
Insulin glargine and malignancy: an unwarranted alarm
Pocock, S., & Smeeth, L. L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61307-6 · Cited by 150
Metformin and the Incidence of Prostate Cancer in Patients with Type 2 Diabetes
Azoulay, L., Dell’Aniello, S., Gagnon, B., Pollak, M., & Suissa, S. (2011) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0940 · Cited by 145
Diabetes and Risk of Prostate Cancer
Tseng, C. (2011) · Diabetes Care · doi:10.2337/dc10-1640 · Cited by 123
Monami, M., Luzzi, C., Lamanna, C., Chiasserini, V., Addante, F., Desideri, C. M., Masotti, G., Marchionni, N., & Mannucci, E. (2006) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.642 · Cited by 121
Are sulphonylureas all the same? A cohort study on cardiovascular and cancer‐related mortality
Monami, M., Balzi, D., Lamanna, C., Barchielli, A., Masotti, G., Buiatti, E., Marchionni, N., & Mannucci, E. (2007) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.736 · Cited by 119
Metformin and Cancer Occurrence in Insulin-Treated Type 2 Diabetic Patients
Monami, M., Colombi, C., Balzi, D., Dicembrini, I., Giannini, S., Melani, C., Vitale, V., Romano, D., Barchielli, A., Marchionni, N., et al. (2010) · Diabetes Care · doi:10.2337/dc10-1287 · Cited by 111
Holly, J., Gunnell, D., & Smith, G. D. (1999) · Journal of Endocrinology · doi:10.1677/joe.0.1620321 · Cited by 111
Antidiabetic Medication and Prostate Cancer Risk: A Population-based Case-Control Study
Murtola, T. J., Tammela, T. L. J., Lahtela, J. T., & Auvinen, A. P. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwn190 · Cited by 107
Metformin Decelerates Aging and Development of Mammary Tumors in HER-2/neu Transgenic Mice
Anisimov, V. N., Egormin, P. A., Берштейн, Л. М., Zabezhinskiĭ, M. A., Piskunova, T. S., Popovich, I. G., & Semenchenko, A. V. (2005) · Bulletin of Experimental Biology and Medicine · doi:10.1007/s10517-005-0389-9 · Cited by 99
Managing Type 2 Diabetes: Going Beyond Glycemic Control
STOLAR, M. W., Hoogwerf, B. J., Boyle, P. J., Gorshow, S. M., & Wales, D. O. (2008) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2008.14.s5-b.1 · Cited by 98
Steinberg, G. R., Macaulay, S. L., Febbraio, M. A., & Kemp, B. E. (2006) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/y06-005 · Cited by 93
Diabetes Mellitus Type 2 – An Independent Risk Factor for Cancer?
Grote, V. A., Becker, S., & Kaaks, R. (2010) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1243193 · Cited by 90
Cancer incidence among patients treated with antidiabetic pharmacotherapy
Oliveria, S. A., Koro, C. E., Yood, M. U., & Sowell, M. O. (2008) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2007.11.002 · Cited by 89
Low HDL Cholesterol, Metformin Use, and Cancer Risk in Type 2 Diabetes
Yang, X., So, W. Y., Ronald, C. W., Kong, A. P. S., Lee, H. M., Yu, L. W. L., Chow, C., Ozaki, R., Ko, G. T. C., & Chan, J. C. N. (2010) · Diabetes Care · doi:10.2337/dc10-1509 · Cited by 68
Clinical usage of hypolipidemic and antidiabetic drugs in the prevention and treatment of cancer
Berstein, L. M. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.11.011 · Cited by 67
Diabetes therapy and cancer risk: causal effects and other plausible explanations
Hernández–Díaz, S., & Adami, H. (2010) · Diabetologia · doi:10.1007/s00125-010-1675-2 · Cited by 52
Relation between Insulin Resistance and Breast Cancer among Chilean Women
Garmendia, M. L., Pereira, A. P. R., Alvarado, M. E., & Atalah, E. (2007) · Annals of Epidemiology · doi:10.1016/j.annepidem.2007.01.037 · Cited by 46
Diabetes mellitus, medications for type 2 diabetes mellitus, and cancer risk
Vecchia, C. L. (2011) · Metabolism · doi:10.1016/j.metabol.2011.03.011 · Cited by 21
Cited by
Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Tempero, M. A., Malafa, M. P., Al-Hawary, M., Behrman, S. W., Benson, A. B., Cardin, D. B., Chiorean, E. G., Chung, V., Czito, B., Del Chiaro, M., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0017 · Cited by 1,304
Metabolism of Inflammation Limited by AMPK and Pseudo-Starvation
O'Neill, L. A. J., & Hardie, D. G. (2013) · Nature · doi:10.1038/nature11862 · Cited by 1,133
AMPK, insulin resistance, and the metabolic syndrome
Ruderman, N. B., Carling, D., Prentki, M., & Cacicedo, J. M. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67227 · Cited by 873
Augustin, L. S. A., Kendall, C. W. C., Jenkins, D. J. A., Willett, W. C., Astrup, A., Barclay, A. W., Björck, I., Brand-Miller, J. C., Brighenti, F., Buyken, A. E., et al. (2015) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2015.05.005 · Cited by 707
Self-citationGandini, S., Puntoni, M., Heckman-Stoddard, B. M., Dunn, B. K., Ford, L., DeCensi, A., & Szabo, E. (2014) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0424 · Cited by 457
Metadata
- Authors
- Soranna, D., Scotti, L., Zambon, A., Bosetti, C., Grassi, G., Catapano, A., La Vecchia, C., Mancia, G., & Corrao, G.
- Venue
- The Oncologist
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-05-29
- Volume
- 17
- Issue
- 6
- Pages
- 813-822
- ISSN
- 1083-7159 (ISSN-L)
- 1549-490X
- OpenAlex
- W2119184048
- Cited by
- 274
- References
- 58
- FWCI
- 2.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.